Larimar director-linked entity granted 55,150 stock options
Larimar Therapeutics, Inc. disclosed that an entity associated with director Jonathan S. Leff received a grant of stock options covering 55,150 shares of common stock.
Rhea-AI Filing Summary
Larimar Therapeutics, Inc. disclosed that an entity associated with director Jonathan S. Leff received a grant of stock options covering 55,150 shares of common stock. The options have an exercise price of $3.33 per share, expire on May 19, 2036, and were granted as compensation.
According to the disclosure, Leff, a partner in Deerfield Management Company, L.P., has no pecuniary interest in these options and disclaims beneficial ownership, holding them for the benefit and at the direction of Deerfield Management Company, L.P. The options vest on the earlier of May 19, 2027 or the company’s next annual stockholder meeting, subject to his continued service on the board.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 55,150 shares
Grant/Award
1 txn
Insider
LEFF JONATHAN S
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 55,150 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 55,150 contracts (Direct)
Footnotes (2)
- F1. The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P.
- F2. The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.
Key Figures
Options granted: 55,150 options
Exercise price: $3.33 per share
Expiration date: May 19, 2036
+2 more
5 metrics
Options granted
55,150 options
Stock Option (Right to Buy) granted on May 19, 2026
Exercise price
$3.33 per share
Conversion or exercise price for granted options
Expiration date
May 19, 2036
Options expire on this date if unexercised
Post-transaction derivative holdings
55,150 options
Total derivative securities following this grant
Vesting date
Earlier of May 19, 2027 or next annual meeting
Vesting contingent on continued board service
Key Terms
Stock Option (Right to Buy), pecuniary interest, beneficial ownership, vest, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
pecuniary interest financial
"has no pecuniary interest in the securities reported herein"
beneficial ownership financial
"disclaims beneficial ownership of such securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
vest financial
"The options vest on the earlier of (a) May 19, 2027 or (b) the date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
continued service on the Board of Directors financial
"subject to the Reporting Person's continued service on the Board of Directors"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Larimar Therapeutics (LRMR) report for Jonathan S. Leff?
Larimar Therapeutics reported a grant of stock options covering 55,150 shares of common stock to an entity associated with director Jonathan S. Leff. These options were issued as compensation and are structured as a right to buy shares at a fixed exercise price.
What is the exercise price and expiration date of the new LRMR stock options?
The granted stock options have an exercise price of $3.33 per share and expire on May 19, 2036. This means the holder may purchase Larimar Therapeutics common shares at $3.33 any time before that expiration date, once the options are vested and exercisable.
When do the newly granted Larimar Therapeutics (LRMR) options vest?
The options vest on the earlier of May 19, 2027 or the date of Larimar Therapeutics’ next annual meeting of stockholders. Vesting in either case depends on Jonathan S. Leff’s continued service on the company’s board of directors through that vesting date.
Does Jonathan S. Leff personally benefit from the LRMR option grant?
The filing states that Jonathan S. Leff has no pecuniary interest in the reported options and disclaims beneficial ownership. He holds the options for the benefit, and at the direction, of Deerfield Management Company, L.P., where he is a partner, rather than for his personal economic gain.
How many LRMR derivative securities does the entity hold after this option grant?
Following the transaction, the reporting line shows 55,150 derivative securities in the form of stock options. These represent rights to acquire up to 55,150 shares of Larimar Therapeutics common stock, subject to vesting terms and the stated expiration date in 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
